A new gene therapy approach has been developed by scientists from Trinity College Dublin, which could help treat an eye disease that leads to loss of vision.
For the study, published in the Frontiers in Neuroscience, they developed a therapy for Dominant optic atrophy(DOA) that typically degenerates the optic nerves.
The new gene therapy protected the visual function of mice after they were treated with a chemical that targeted their mitochondria, the scientists have said.
In humans, they found the therapy improved mitochondrial performance in those cells that contained mutations in the OPA1 gene. It has been concluded that the therapy could potentially be beneficial for DOA, caused due to OPA1 mutations.